Business
Tarsus Reports Second Quarter 2022 Financial Results and Recent Business Achievements
TP-03 for the treatment of Demodex blepharitis met all endpoints in the Saturn-2 Phase 3 trial; NDA submission expected this year Initiated Ersa Phase 2a
About this update from Tarsus Pharmaceuticals, Inc.
[{"type":"text","content":"TP-03 for the treatment of Demodex blepharitis met all endpoints in the Saturn-2 Phase 3 trial; NDA submission expected this year Initiated Ersa Phase 2a trial evaluating TP-03 for the treatment of Meibomian Gland Disease Cash runway anticipated into at least 2026 for the commercial launch of TP-03 and continued pipeline development IRVINE, Calif., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for eye diseases, today announced financial results for the second quarter ended June 30, 2022, and recent business achievements. “We continued to execute on our top priority of advancing TP-03 for the treatment of Demodex blepharitis, including preparing for NDA submission this year. We are also expanding the commercial team and seeing growing disease awareness as we generate momentum towards a potential commercial launch next year,” said Bobak Azamian, M.D., Ph.D., President and Chief Executive Officer of Tarsus. “Simultaneously, we’ve taken positive steps to advance our pipeline, including initiating our clinical program for MGD, and preparing for the start of two additional Phase 2 studies in Lyme disease prevention and Rosacea. These milestones, along with our strengthened balance sheet, are important steps toward our goal of becoming a leading eye pharmaceutical company.” Recent Business Highlights and Corporate Update NDA submission of TP-03 for Demodex blepharitis (DB) expected this yearTP-03 met the primary and all secondary endpoints, resolved DB and was safe and well-tolerated in Saturn-2 Phase 3, the second and final pivotal trialInitiated Ersa Phase 2a trial evaluating TP-03 for the treatment of Meibomian Gland Disease, another highly prevalent eyelid margin diseaseData from the Callisto Phase 1b trial of TP-05, a novel, oral, non-vaccine potential therapeutic for the prevention of Lyme disease, expected this yearCash runway anticipated into at least 2026 $245 million of cash as of June 30, 2022, including Q2 2022 net proceeds of $74 million from follow-on equity raise and a $15 million milestone from China out-license$30 million in expected milestones through 2024 from China out-license with $15 million in H2 2022 2022 Milestones ProgramMilestoneAnticipated IndicationH1 2022H2 2022TP...